ACM
NBIX icon

AlphaCrest Capital Management’s Neurocrine Biosciences NBIX Stock Holding History

AlphaCrest Capital Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-28,555
Closed -$3.03M – 745
2022
Q3 		$3.03M Buy
28,555
+851
+3% +$86.3K 0.18% 99
2022
Q2 		$2.7M Buy
27,704
+10,304
+59% +$951K 0.13% 193
2022
Q1 		$1.63M Sell
17,400
-14,463
-45% -$1.23M 0.09% 321
2021
Q4 		$2.71M Buy
31,863
+18,016
+130% +$1.66M 0.1% 272
2021
Q3 		$1.33M Sell
13,847
-10,941
-44% -$1.03M 0.07% 488
2021
Q2 		$2.41M Buy
24,788
+13,252
+115% +$1.27M 0.1% 296
2021
Q1 		$1.12M Buy
11,536
+443
+4% +$46.5K 0.06% 450
2020
Q4 		$1.06M Buy
11,093
+2,003
+22% +$193K 0.09% 298
2020
Q3 		$874K Buy
9,090
+7,205
+382% +$833K 0.1% 311
2020
Q2 		$230K Sell
1,885
-10,813
-85% -$1.19M 0.04% 770
2020
Q1 		$1.1M Sell
12,698
-375
-3% -$36.7K 0.13% 240
2019
Q4 		$1.41M Sell
13,073
-398
-3% -$41.7K 0.12% 206
2019
Q3 		$1.21M Buy
13,471
+231
+2% +$21.6K 0.07% 468
2019
Q2 		$1.12M Buy
13,240
+8,086
+157% +$664K 0.1% 343
2019
Q1 		$454K Buy
+5,154
New +$431K 0.07% 499

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

AlphaCrest Capital Management's NBIX Position: Q4 2022 in Review

AlphaCrest Capital Management sold out of Neurocrine Biosciences (NBIX) in Q4 2022, closing a stake of 28,555 shares — an estimated $3.03M sold.

AlphaCrest Capital Management first reported a position in NBIX in Q1 2019 and held it in 15 quarters. The position peaked at $3.03M in Q3 2022. 529 funds tracked by Wall St. Rank hold NBIX as of Q4 2022.

  • AlphaCrest Capital Management reported no remaining Neurocrine Biosciences position as of Q4 2022 after selling out during the quarter.
  • AlphaCrest Capital Management sold 28,555 Neurocrine Biosciences shares in Q4 2022, an estimated $3.03M.
  • AlphaCrest Capital Management first reported a position in Neurocrine Biosciences in Q1 2019 and held it in 15 quarters.
  • AlphaCrest Capital Management's Neurocrine Biosciences position peaked at $3.03M in Q3 2022.
  • 529 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2022.

Based on AlphaCrest Capital Management's 13F filing for Q4 2022.